A5031281244- SARS-CoV-2 detection and testing
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- Bacillus and Francisella bacterial research
- Endoplasmic Reticulum Stress and Disease
- Genetic Neurodegenerative Diseases
- Fibromyalgia and Chronic Fatigue Syndrome Research
United States Food and Drug Administration
2021-2022
Center for Biologics Evaluation and Research
2021-2022
The rapid spread of the highly contagious Omicron variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) along with its high number mutations in spike gene has raised alarms about effectiveness current medical countermeasures. To address this concern, we measured neutralization BA.1 pseudovirus by postvaccination serum samples after two and three immunizations Pfizer/BioNTech162b2 SARS-CoV-2 mRNA (Pfizer/BNT162b2) vaccine, convalescent from unvaccinated individuals infected...
Abstract The SARS-CoV-2 B.1.617 lineage variants, Kappa (B.1.617.1) and Delta (B.1.617.2, AY) emerged during the second wave of infections in India, but variants have become dominant worldwide continue to evolve. spike proteins B.1.617.1, B.1.617.2, AY.1 several substitutions receptor binding domain (RBD), including L452R+E484Q, L452R+T478K, K417N+L452R+T478K, respectively, that could potentially reduce effectiveness therapeutic antibodies current vaccines. Here we compared their single...